You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePentobarbital
Accession NumberDB00312  (APRD01174)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236)
Structure
Thumb
Synonyms
5-Ethyl-5-(1-methyl-butyl)-pyrimidine-2,4,6-trione
5-Ethyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione
5-ethyl-5-(1-methylbutyl)barbituric acid
5-ethyl-5-(sec-pentyl)barbituric acid
Nembutal
Pentobarbital
Pentobarbitone
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Nembutal Sodium Cap 100mgcapsule100 mgoralAbbott Laboratories, Limited1951-12-311997-08-18Canada
Nembutal Sodium Inj 50mg/mlsolution50 mgintramuscular; intravenousAbbott Laboratories, Limited1976-12-312008-06-06Canada
Nova Rectal Sup 25mgsuppository25 mgrectalSabex Inc1984-12-311999-08-12Canada
Nova Rectal Sup 50mgsuppository50 mgrectalSabex Inc1984-12-312001-08-02Canada
Novo-pentobarb 100mgcapsule100 mgoralNovopharm Limited1967-12-312005-08-10Canada
Pentobarbital Sodium Cap 50mgcapsule50 mgoralSands Pharm1972-12-311996-09-10Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Nembutal Sodiuminjection50 mg/mLintramuscular; intravenousOak Pharmaceuticals, Inc. (Subsidiary of Akorn, Inc.)1973-09-19Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
NembutalLundbeck
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Pentobarbital Sodium
Thumb
  • InChI Key: QGMRQYFBGABWDR-UHFFFAOYNA-M
  • Monoisotopic Mass: 248.113687095
  • Average Mass: 248.254
DBSALT000442
Categories
UNIII4744080IR
CAS number76-74-4
WeightAverage: 226.2722
Monoisotopic: 226.131742452
Chemical FormulaC11H18N2O3
InChI KeyInChIKey=WEXRUCMBJFQVBZ-UHFFFAOYSA-N
InChI
InChI=1S/C11H18N2O3/c1-4-6-7(3)11(5-2)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)
IUPAC Name
5-ethyl-5-(pentan-2-yl)-1,3-diazinane-2,4,6-trione
SMILES
CCCC(C)C1(CC)C(=O)NC(=O)NC1=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazines
Sub ClassPyrimidines and pyrimidine derivatives
Direct ParentBarbituric acid derivatives
Alternative Parents
Substituents
  • Barbiturate
  • Ureide
  • 1,3-diazinane
  • Urea
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the short-term treatment of insomnia.
PharmacodynamicsPentobarbital, a barbiturate, is used for the treatment of short term insomnia. It belongs to a group of medicines called central nervous system (CNS) depressants that induce drowsiness and relieve tension or nervousness. Little analgesia is conferred by barbiturates; their use in the presence of pain may result in excitation.
Mechanism of actionPentobarbital binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged. All of these effects are associated with marked decreases in GABA-sensitive neuronal calcium conductance (gCa). The net result of barbiturate action is acute potentiation of inhibitory GABAergic tone. Barbiturates also act through potent (if less well characterized) and direct inhibition of excitatory AMPA-type glutamate receptors, resulting in a profound suppression of glutamatergic neurotransmission.
Related Articles
AbsorptionBarbiturates are absorbed in varying degrees following oral, rectal, or parenteral administration.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

by hepatic microsomal enzyme system

Route of eliminationBarbiturates are metabolized primarily by the hepatic microsomal enzyme system, and the metabolic products are excreted in the urine, and less commonly, in the feces. Approximately 25 to 50 percent of a dose of aprobarbital or phenobarbital is eliminated unchanged in the urine, whereas the amount of other barbiturates excreted unchanged in the urine is negligible.
Half life5 to 50 hours (dose dependent)
ClearanceNot Available
ToxicitySymptoms of an overdose typically include sluggishness, incoordination, difficulty in thinking, slowness of speech, faulty judgment, drowsiness or coma, shallow breathing, staggering, and in severe cases coma and death.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9156
Blood Brain Barrier+0.9713
Caco-2 permeable-0.5926
P-glycoprotein substrateSubstrate0.5947
P-glycoprotein inhibitor INon-inhibitor0.6155
P-glycoprotein inhibitor IINon-inhibitor0.9218
Renal organic cation transporterNon-inhibitor0.923
CYP450 2C9 substrateNon-substrate0.7789
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateNon-substrate0.7066
CYP450 1A2 substrateNon-inhibitor0.9086
CYP450 2C9 inhibitorNon-inhibitor0.7484
CYP450 2D6 inhibitorNon-inhibitor0.9301
CYP450 2C19 inhibitorNon-inhibitor0.711
CYP450 3A4 inhibitorNon-inhibitor0.9522
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9276
Ames testNon AMES toxic0.6789
CarcinogenicityNon-carcinogens0.89
BiodegradationNot ready biodegradable0.9603
Rat acute toxicity3.2266 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9685
hERG inhibition (predictor II)Non-inhibitor0.8771
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Ovation pharmaceuticals inc
  • Lannett co inc
  • Vitarine pharmaceuticals inc
  • Whiteworth towne paulsen inc
  • Anabolic inc
  • Elkins sinn div ah robins co inc
  • Everylife
  • Halsey drug co inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Parke davis div warner lambert co
  • L perrigo co
  • Purepac pharmaceutical co
  • Valeant pharmaceuticals international
  • Watson laboratories inc
  • Wyeth ayerst laboratories
  • Lundbeck inc
  • Nexgen pharma inc
Packagers
Dosage forms
FormRouteStrength
Injectionintramuscular; intravenous50 mg/mL
Capsuleoral100 mg
Solutionintramuscular; intravenous50 mg
Suppositoryrectal25 mg
Suppositoryrectal50 mg
Capsuleoral50 mg
Prices
Unit descriptionCostUnit
Pentobarbital sodium powder27.0USD g
Nembutal sodium 50 mg/ml via20.65USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point129.5 °CPhysProp
water solubility679 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.10HANSCH,C ET AL. (1995)
logS-2.52ADME Research, USCD
pKa8.11 (at 25 °C)SERJEANT,EP & DEMPSEY,B (1979)
Predicted Properties
PropertyValueSource
Water Solubility0.864 mg/mLALOGPS
logP2.16ALOGPS
logP1.89ChemAxon
logS-2.4ALOGPS
pKa (Strongest Acidic)8.48ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area75.27 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity58 m3·mol-1ChemAxon
Polarizability23.41 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.77 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Positivesplash10-004i-1290000000-90bfbd79bea4fe2b007bView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Positivesplash10-0bti-1900000000-7e31dcdb272669c13101View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Positivesplash10-01bc-9100000000-c9fe8276b8137dc73d20View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, Negativesplash10-004i-3980000000-84ea889a0fae4bed224bView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, Negativesplash10-0006-9500000000-c226fe2dfb4ee13e4ae8View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, Negativesplash10-000x-9500000000-cd4190b9c110ee5e4428View in MoNA
MSMass Spectrum (Electron Ionization)splash10-0a4l-6900000000-a65d8c67e006ad448814View in MoNA
References
Synthesis ReferenceNot Available
General References
  1. Knodell RG, Spector MH, Brooks DA, Keller FX, Kyner WT: Alterations in pentobarbital pharmacokinetics in response to parenteral and enteral alimentation in the rat. Gastroenterology. 1980 Dec;79(6):1211-6. [PubMed:6777235 ]
External Links
ATC CodesN05CA01
AHFS Codes
  • 28:24.04
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (50.3 KB)
Interactions
Drug Interactions
Drug
4-AndrostenedioneThe serum concentration of 4-Androstenedione can be decreased when it is combined with Pentobarbital.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Pentobarbital is combined with 7-Nitroindazole.
AbirateroneThe serum concentration of Abiraterone can be decreased when it is combined with Pentobarbital.
AbirateroneThe metabolism of Pentobarbital can be decreased when combined with Abiraterone.
AcebutololPentobarbital may increase the hypotensive activities of Acebutolol.
AcenocoumarolThe metabolism of Acenocoumarol can be increased when combined with Pentobarbital.
AcepromazineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Aceprometazine.
AcetaminophenThe metabolism of Acetaminophen can be increased when combined with Pentobarbital.
AcetazolamidePentobarbital may increase the hypotensive activities of Acetazolamide.
AdinazolamThe metabolism of Adinazolam can be increased when combined with Pentobarbital.
adipiplonThe risk or severity of adverse effects can be increased when Pentobarbital is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Agomelatine.
AlbendazoleThe metabolism of Albendazole can be increased when combined with Pentobarbital.
AlclometasoneThe serum concentration of Alclometasone can be decreased when it is combined with Pentobarbital.
AldesleukinPentobarbital may increase the hypotensive activities of Aldesleukin.
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Pentobarbital.
AlfaxaloneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Alfentanil.
AlfuzosinThe metabolism of Alfuzosin can be increased when combined with Pentobarbital.
AliskirenPentobarbital may increase the hypotensive activities of Aliskiren.
AllylestrenolThe metabolism of Allylestrenol can be increased when combined with Pentobarbital.
AlmotriptanThe metabolism of Almotriptan can be increased when combined with Pentobarbital.
AlogliptinThe metabolism of Alogliptin can be increased when combined with Pentobarbital.
AlosetronThe metabolism of Alosetron can be increased when combined with Pentobarbital.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Alprazolam.
AlprenololThe serum concentration of Alprenolol can be decreased when it is combined with Pentobarbital.
AmbrisentanThe metabolism of Ambrisentan can be increased when combined with Pentobarbital.
AmbroxolThe metabolism of Ambroxol can be increased when combined with Pentobarbital.
AmcinonideThe serum concentration of Amcinonide can be decreased when it is combined with Pentobarbital.
AmiloridePentobarbital may increase the hypotensive activities of Amiloride.
AmineptineThe metabolism of Amineptine can be increased when combined with Pentobarbital.
AminophenazoneThe metabolism of Aminophenazone can be increased when combined with Pentobarbital.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Pentobarbital.
AmiodaroneThe metabolism of Amiodarone can be increased when combined with Pentobarbital.
AmisulprideThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Amitriptyline.
AmlodipinePentobarbital may increase the hypotensive activities of Amlodipine.
AmobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Amperozide.
AmprenavirThe metabolism of Amprenavir can be increased when combined with Pentobarbital.
AmrinoneThe metabolism of Amrinone can be increased when combined with Pentobarbital.
Amyl NitritePentobarbital may increase the hypotensive activities of Amyl Nitrite.
AntipyrineThe metabolism of Antipyrine can be increased when combined with Pentobarbital.
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Pentobarbital.
ApraclonidinePentobarbital may increase the hypotensive activities of Apraclonidine.
ApremilastThe serum concentration of Apremilast can be decreased when it is combined with Pentobarbital.
AprepitantThe metabolism of Aprepitant can be increased when combined with Pentobarbital.
ArformoterolThe metabolism of Arformoterol can be increased when combined with Pentobarbital.
ArgatrobanThe metabolism of Argatroban can be increased when combined with Pentobarbital.
AripiprazoleThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Aripiprazole.
ArmodafinilThe metabolism of Pentobarbital can be decreased when combined with Armodafinil.
ArotinololThe serum concentration of Arotinolol can be decreased when it is combined with Pentobarbital.
ArtemetherThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Pentobarbital resulting in a loss in efficacy.
ArticaineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Asenapine.
AstemizoleThe metabolism of Astemizole can be increased when combined with Pentobarbital.
AtazanavirThe metabolism of Atazanavir can be increased when combined with Pentobarbital.
AtenololPentobarbital may increase the hypotensive activities of Atenolol.
AtorvastatinThe metabolism of Atorvastatin can be increased when combined with Pentobarbital.
AvanafilThe metabolism of Avanafil can be increased when combined with Pentobarbital.
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Pentobarbital.
AzaperoneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Azaperone.
AzelastinePentobarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Pentobarbital.
AzelnidipineThe metabolism of Azelnidipine can be increased when combined with Pentobarbital.
Azilsartan medoxomilPentobarbital may increase the hypotensive activities of Azilsartan medoxomil.
AzimilideThe metabolism of Azimilide can be increased when combined with Pentobarbital.
AzithromycinThe metabolism of Azithromycin can be increased when combined with Pentobarbital.
BaclofenThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Baclofen.
BanoxantroneThe metabolism of Banoxantrone can be increased when combined with Pentobarbital.
BarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Barbital.
BarnidipineThe metabolism of Barnidipine can be increased when combined with Pentobarbital.
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Pentobarbital.
BedaquilineThe serum concentration of Bedaquiline can be decreased when it is combined with Pentobarbital.
BefunololThe serum concentration of Befunolol can be decreased when it is combined with Pentobarbital.
BenazeprilPentobarbital may increase the hypotensive activities of Benazepril.
BendroflumethiazidePentobarbital may increase the orthostatic hypotensive activities of Bendroflumethiazide.
BenidipineThe metabolism of Benidipine can be increased when combined with Pentobarbital.
BenzocaineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Benzocaine.
BenzphetamineThe metabolism of Benzphetamine can be increased when combined with Pentobarbital.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Benzyl alcohol.
BepridilThe metabolism of Bepridil can be increased when combined with Pentobarbital.
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Pentobarbital.
BetaxololPentobarbital may increase the hypotensive activities of Betaxolol.
BevantololThe serum concentration of Bevantolol can be decreased when it is combined with Pentobarbital.
BexaroteneThe metabolism of Bexarotene can be increased when combined with Pentobarbital.
BezafibrateThe metabolism of Bezafibrate can be increased when combined with Pentobarbital.
BicalutamideThe metabolism of Bicalutamide can be increased when combined with Pentobarbital.
BisoprololPentobarbital may increase the hypotensive activities of Bisoprolol.
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Pentobarbital.
BopindololThe serum concentration of Bopindolol can be decreased when it is combined with Pentobarbital.
BortezomibThe serum concentration of Bortezomib can be decreased when it is combined with Pentobarbital.
BortezomibThe metabolism of Pentobarbital can be decreased when combined with Bortezomib.
BosentanThe metabolism of Bosentan can be increased when combined with Pentobarbital.
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Pentobarbital.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Pentobarbital.
BretyliumPentobarbital may increase the hypotensive activities of Bretylium.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.
BrimonidinePentobarbital may increase the hypotensive activities of Brimonidine.
BrinzolamideThe metabolism of Brinzolamide can be increased when combined with Pentobarbital.
BromazepamThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Bromazepam.
BromocriptineThe metabolism of Bromocriptine can be increased when combined with Pentobarbital.
BrompheniramineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Brotizolam.
BudesonideThe serum concentration of Budesonide can be decreased when it is combined with Pentobarbital.
BufuralolThe serum concentration of Bufuralol can be decreased when it is combined with Pentobarbital.
BumetanidePentobarbital may increase the hypotensive activities of Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Pentobarbital.
BupranololThe serum concentration of Bupranolol can be decreased when it is combined with Pentobarbital.
BuprenorphineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Buprenorphine.
BupropionThe metabolism of Bupropion can be increased when combined with Pentobarbital.
BuspironeThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Buspirone.
BusulfanThe metabolism of Busulfan can be increased when combined with Pentobarbital.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Pentobarbital.
ButacaineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Butorphanol.
CabazitaxelThe metabolism of Cabazitaxel can be increased when combined with Pentobarbital.
CabergolineThe metabolism of Cabergoline can be increased when combined with Pentobarbital.
CabozantinibThe serum concentration of Cabozantinib can be decreased when it is combined with Pentobarbital.
CaffeineThe metabolism of Caffeine can be increased when combined with Pentobarbital.
CalcitriolThe metabolism of Calcitriol can be increased when combined with Pentobarbital.
CanagliflozinPentobarbital may increase the hypotensive activities of Canagliflozin.
CandesartanPentobarbital may increase the hypotensive activities of Candesartan.
CannabidiolThe serum concentration of Cannabidiol can be decreased when it is combined with Pentobarbital.
CaptoprilPentobarbital may increase the hypotensive activities of Captopril.
CarbamazepineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Carbamazepine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Carfentanil.
CariprazineThe metabolism of Cariprazine can be increased when combined with Pentobarbital.
CarisoprodolThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Carisoprodol.
CarteololPentobarbital may increase the hypotensive activities of Carteolol.
CarvedilolPentobarbital may increase the hypotensive activities of Carvedilol.
CelecoxibThe metabolism of Celecoxib can be increased when combined with Pentobarbital.
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Pentobarbital.
CephalexinThe metabolism of Cephalexin can be increased when combined with Pentobarbital.
CeritinibThe serum concentration of Ceritinib can be decreased when it is combined with Pentobarbital.
CerivastatinThe metabolism of Cerivastatin can be increased when combined with Pentobarbital.
CetirizineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Cetirizine.
CevimelineThe metabolism of Cevimeline can be increased when combined with Pentobarbital.
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be increased when combined with Pentobarbital.
Chloral hydrateThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Chloral hydrate.
ChloramphenicolThe metabolism of Pentobarbital can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Chlordiazepoxide.
ChlormezanoneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Chloroprocaine.
ChloroquineThe metabolism of Chloroquine can be increased when combined with Pentobarbital.
ChlorothiazidePentobarbital may increase the orthostatic hypotensive activities of Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Chlorprothixene.
ChlorthalidonePentobarbital may increase the orthostatic hypotensive activities of Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Cholecalciferol can be increased when combined with Pentobarbital.
CiclesonideThe serum concentration of Ciclesonide can be decreased when it is combined with Pentobarbital.
CilazaprilPentobarbital may increase the hypotensive activities of Cilazapril.
CilnidipineThe metabolism of Cilnidipine can be increased when combined with Pentobarbital.
CilostazolThe metabolism of Cilostazol can be increased when combined with Pentobarbital.
CimetidineThe metabolism of Pentobarbital can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Cinacalcet can be increased when combined with Pentobarbital.
CinchocaineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Cinchocaine.
CinnarizineThe metabolism of Cinnarizine can be increased when combined with Pentobarbital.
CisaprideThe metabolism of Cisapride can be increased when combined with Pentobarbital.
CitalopramThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Citalopram.
CitalopramThe metabolism of Pentobarbital can be decreased when combined with Citalopram.
ClarithromycinThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Pentobarbital.
ClemastineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Clemastine.
ClevidipinePentobarbital may increase the hypotensive activities of Clevidipine.
ClidiniumThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Clidinium.
ClindamycinThe metabolism of Clindamycin can be increased when combined with Pentobarbital.
ClobazamThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Clobazam.
Clobetasol propionateThe serum concentration of Clobetasol propionate can be decreased when it is combined with Pentobarbital.
ClocortoloneThe serum concentration of Clocortolone can be decreased when it is combined with Pentobarbital.
ClofazimineThe metabolism of Clofazimine can be increased when combined with Pentobarbital.
ClofibrateThe metabolism of Clofibrate can be increased when combined with Pentobarbital.
clomethiazoleThe risk or severity of adverse effects can be increased when Pentobarbital is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Clonazepam.
ClonidinePentobarbital may increase the hypotensive activities of Clonidine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Pentobarbital.
ClopidogrelThe metabolism of Clopidogrel can be increased when combined with Pentobarbital.
ClorazepateThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Clorazepate.
ClotiazepamThe metabolism of Clotiazepam can be increased when combined with Pentobarbital.
ClotrimazoleThe metabolism of Pentobarbital can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Pentobarbital.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Pentobarbital.
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Pentobarbital.
CocaineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Codeine.
ColchicineThe metabolism of Colchicine can be increased when combined with Pentobarbital.
ConivaptanThe metabolism of Conivaptan can be increased when combined with Pentobarbital.
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be increased when combined with Pentobarbital.
Cortisone acetateThe serum concentration of Cortisone acetate can be decreased when it is combined with Pentobarbital.
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Pentobarbital.
CyclizineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Cyclobenzaprine.
CyclophosphamideThe metabolism of Cyclophosphamide can be increased when combined with Pentobarbital.
CyclosporineThe metabolism of Cyclosporine can be increased when combined with Pentobarbital.
CyproheptadineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Cyproheptadine.
CytarabineThe metabolism of Cytarabine can be increased when combined with Pentobarbital.
DabrafenibThe serum concentration of Pentobarbital can be decreased when it is combined with Dabrafenib.
DabrafenibThe metabolism of Dabrafenib can be increased when combined with Pentobarbital.
DaclatasvirThe serum concentration of Daclatasvir can be decreased when it is combined with Pentobarbital.
DantroleneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dantrolene.
DapagliflozinPentobarbital may increase the hypotensive activities of Dapagliflozin.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Pentobarbital.
DapoxetineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dapoxetine.
DapsoneThe metabolism of Dapsone can be increased when combined with Pentobarbital.
DarifenacinThe metabolism of Darifenacin can be increased when combined with Pentobarbital.
DarodipineThe metabolism of Darodipine can be increased when combined with Pentobarbital.
DarunavirThe metabolism of Darunavir can be increased when combined with Pentobarbital.
DasabuvirThe metabolism of Dasabuvir can be increased when combined with Pentobarbital.
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Pentobarbital.
DaunorubicinThe metabolism of Daunorubicin can be increased when combined with Pentobarbital.
DehydroepiandrosteroneThe serum concentration of Dehydroepiandrosterone can be decreased when it is combined with Pentobarbital.
dehydroepiandrosterone sulfateThe serum concentration of dehydroepiandrosterone sulfate can be decreased when it is combined with Pentobarbital.
DelavirdineThe metabolism of Delavirdine can be increased when combined with Pentobarbital.
deramciclaneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Desloratadine.
DesoximetasoneThe serum concentration of Desoximetasone can be decreased when it is combined with Pentobarbital.
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be decreased when it is combined with Pentobarbital.
DesvenlafaxineThe metabolism of Desvenlafaxine can be increased when combined with Pentobarbital.
DetomidineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Detomidine.
DexamethasoneThe serum concentration of Dexamethasone can be decreased when it is combined with Pentobarbital.
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be decreased when it is combined with Pentobarbital.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dexbrompheniramine.
DexmedetomidinePentobarbital may increase the hypotensive activities of Dexmedetomidine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Pentobarbital.
DextromethorphanThe metabolism of Dextromethorphan can be increased when combined with Pentobarbital.
DextromoramideThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Diazepam.
DiclofenacThe metabolism of Diclofenac can be increased when combined with Pentobarbital.
DiclofenamidePentobarbital may increase the hypotensive activities of Diclofenamide.
DicoumarolThe metabolism of Dicoumarol can be increased when combined with Pentobarbital.
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Pentobarbital.
DifenoxinThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Difenoxin.
DiflorasoneThe serum concentration of Diflorasone can be decreased when it is combined with Pentobarbital.
DifluocortoloneThe serum concentration of Difluocortolone can be decreased when it is combined with Pentobarbital.
DifluprednateThe serum concentration of Difluprednate can be decreased when it is combined with Pentobarbital.
DigitoxinThe metabolism of Digitoxin can be increased when combined with Pentobarbital.
DigoxinThe metabolism of Digoxin can be increased when combined with Pentobarbital.
DihydrocodeineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Dihydroergotamine can be increased when combined with Pentobarbital.
DihydroetorphineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dihydromorphine.
DiltiazemPentobarbital may increase the hypotensive activities of Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dimenhydrinate.
DinutuximabPentobarbital may increase the hypotensive activities of Dinutuximab.
DiphenhydramineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Diphenoxylate.
DipyridamolePentobarbital may increase the hypotensive activities of Dipyridamole.
DisopyramideThe metabolism of Disopyramide can be increased when combined with Pentobarbital.
DisulfiramThe metabolism of Disulfiram can be increased when combined with Pentobarbital.
DocetaxelThe metabolism of Docetaxel can be increased when combined with Pentobarbital.
DofetilideThe metabolism of Dofetilide can be increased when combined with Pentobarbital.
DolasetronThe metabolism of Dolasetron can be increased when combined with Pentobarbital.
DomperidoneThe metabolism of Domperidone can be increased when combined with Pentobarbital.
DonepezilThe metabolism of Donepezil can be increased when combined with Pentobarbital.
DoramectinThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Doramectin.
DorzolamideThe metabolism of Dorzolamide can be increased when combined with Pentobarbital.
DosulepinThe metabolism of Dosulepin can be increased when combined with Pentobarbital.
DotarizineThe metabolism of Dotarizine can be increased when combined with Pentobarbital.
DoxazosinPentobarbital may increase the hypotensive activities of Doxazosin.
DoxepinThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Doxepin.
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Pentobarbital.
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Pentobarbital.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.
DoxylamineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Pentobarbital is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.
DronabinolThe serum concentration of Dronabinol can be decreased when it is combined with Pentobarbital.
DronedaroneThe serum concentration of Dronedarone can be decreased when it is combined with Pentobarbital.
DroperidolThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Droperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Drotebanol.
DutasterideThe metabolism of Dutasteride can be increased when combined with Pentobarbital.
DyclonineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Dyclonine.
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Pentobarbital.
EcgonineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Pentobarbital is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Efavirenz.
EfonidipineThe metabolism of Efonidipine can be increased when combined with Pentobarbital.
EletriptanThe metabolism of Eletriptan can be increased when combined with Pentobarbital.
EliglustatThe serum concentration of Eliglustat can be decreased when it is combined with Pentobarbital.
ElvitegravirThe metabolism of Elvitegravir can be increased when combined with Pentobarbital.
EmpagliflozinPentobarbital may increase the hypotensive activities of Empagliflozin.
EnalaprilPentobarbital may increase the hypotensive activities of Enalapril.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Pentobarbital.
EntacaponeThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Entacapone.
EnzalutamideThe serum concentration of Enzalutamide can be decreased when it is combined with Pentobarbital.
EperisoneThe metabolism of Eperisone can be increased when combined with Pentobarbital.
EpinastineThe metabolism of Epinastine can be increased when combined with Pentobarbital.
EplerenonePentobarbital may increase the hypotensive activities of Eplerenone.
EprosartanPentobarbital may increase the hypotensive activities of Eprosartan.
EquileninThe serum concentration of Equilenin can be decreased when it is combined with Pentobarbital.
EquilinThe serum concentration of Equilin can be decreased when it is combined with Pentobarbital.
ErgocalciferolThe metabolism of Ergocalciferol can be increased when combined with Pentobarbital.
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be increased when combined with Pentobarbital.
ErgonovineThe metabolism of Ergonovine can be increased when combined with Pentobarbital.
ErgotamineThe metabolism of Ergotamine can be increased when combined with Pentobarbital.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Pentobarbital.
ErythromycinThe metabolism of Erythromycin can be increased when combined with Pentobarbital.
EscitalopramThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Escitalopram.
Eslicarbazepine acetateThe metabolism of Pentobarbital can be decreased when combined with Eslicarbazepine acetate.
EsmirtazapineThe metabolism of Esmirtazapine can be increased when combined with Pentobarbital.
EsmololPentobarbital may increase the hypotensive activities of Esmolol.
EsomeprazoleThe metabolism of Esomeprazole can be increased when combined with Pentobarbital.
EstazolamThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Estazolam.
EstradiolThe metabolism of Estradiol can be increased when combined with Pentobarbital.
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be increased when combined with Pentobarbital.
EstramustineThe metabolism of Estramustine can be increased when combined with Pentobarbital.
EstroneThe serum concentration of Estrone can be decreased when it is combined with Pentobarbital.
Estrone sulfateThe metabolism of Estrone sulfate can be increased when combined with Pentobarbital.
EszopicloneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Eszopiclone.
Etacrynic acidPentobarbital may increase the hypotensive activities of Etacrynic acid.
EthanolPentobarbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Pentobarbital.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pentobarbital.
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be increased when combined with Pentobarbital.
EthosuximideThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Ethotoin.
Ethyl biscoumacetateThe metabolism of Ethyl biscoumacetate can be increased when combined with Pentobarbital.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Pentobarbital.
EtonogestrelThe metabolism of Etonogestrel can be increased when combined with Pentobarbital.
EtoperidoneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Etoperidone.
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Pentobarbital.
EtoricoxibThe metabolism of Etoricoxib can be increased when combined with Pentobarbital.
EtorphineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Etorphine.
EtravirineThe metabolism of Etravirine can be increased when combined with Pentobarbital.
EverolimusThe serum concentration of Everolimus can be decreased when it is combined with Pentobarbital.
ExemestaneThe serum concentration of Exemestane can be decreased when it is combined with Pentobarbital.
EzogabineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Ezogabine.
FamciclovirThe metabolism of Famciclovir can be increased when combined with Pentobarbital.
FelbamateThe serum concentration of Pentobarbital can be increased when it is combined with Felbamate.
FelbamateThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Felbamate.
FelodipinePentobarbital may increase the hypotensive activities of Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Fencamfamine.
FendilineThe metabolism of Fendiline can be increased when combined with Pentobarbital.
FenfluramineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Fenfluramine.
FenofibrateThe metabolism of Fenofibrate can be increased when combined with Pentobarbital.
FentanylThe serum concentration of Fentanyl can be decreased when it is combined with Pentobarbital.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Pentobarbital.
FesoterodineThe metabolism of Fesoterodine can be increased when combined with Pentobarbital.
FexofenadineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Fexofenadine.
FinasterideThe metabolism of Finasteride can be increased when combined with Pentobarbital.
FingolimodThe metabolism of Fingolimod can be increased when combined with Pentobarbital.
FlibanserinThe serum concentration of Flibanserin can be decreased when it is combined with Pentobarbital.
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Pentobarbital.
FluconazoleThe metabolism of Pentobarbital can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Fludiazepam.
FludrocortisoneThe serum concentration of Fludrocortisone can be decreased when it is combined with Pentobarbital.
FlumethasoneThe serum concentration of Flumethasone can be decreased when it is combined with Pentobarbital.
FlunarizineThe metabolism of Flunarizine can be increased when combined with Pentobarbital.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Pentobarbital.
FlunisolideThe serum concentration of Flunisolide can be decreased when it is combined with Pentobarbital.
FlunitrazepamThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Flunitrazepam.
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Pentobarbital.
FluocinonideThe serum concentration of Fluocinonide can be decreased when it is combined with Pentobarbital.
FluocortoloneThe serum concentration of Fluocortolone can be decreased when it is combined with Pentobarbital.
FluorometholoneThe serum concentration of Fluorometholone can be decreased when it is combined with Pentobarbital.
FluorouracilThe metabolism of Fluorouracil can be increased when combined with Pentobarbital.
FluoxetineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Fluoxetine.
FluoxetineThe metabolism of Pentobarbital can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Fluphenazine.
FluprednideneThe serum concentration of Fluprednidene can be decreased when it is combined with Pentobarbital.
FluprednisoloneThe serum concentration of Fluprednisolone can be decreased when it is combined with Pentobarbital.
FlurandrenolideThe serum concentration of Flurandrenolide can be decreased when it is combined with Pentobarbital.
FlurazepamThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Fluspirilene.
FlutamideThe metabolism of Flutamide can be increased when combined with Pentobarbital.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Pentobarbital.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Fluticasone Propionate.
FluvastatinThe metabolism of Fluvastatin can be increased when combined with Pentobarbital.
FluvoxamineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Fluvoxamine.
FormoterolThe metabolism of Formoterol can be increased when combined with Pentobarbital.
FosamprenavirThe metabolism of Fosamprenavir can be increased when combined with Pentobarbital.
FosinoprilPentobarbital may increase the hypotensive activities of Fosinopril.
FosphenytoinThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Fospropofol.
FulvestrantThe metabolism of Fulvestrant can be increased when combined with Pentobarbital.
FurosemidePentobarbital may increase the hypotensive activities of Furosemide.
GabapentinThe metabolism of Gabapentin can be increased when combined with Pentobarbital.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pentobarbital.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Pentobarbital is combined with gabapentin enacarbil.
GalantamineThe metabolism of Galantamine can be increased when combined with Pentobarbital.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Gamma Hydroxybutyric Acid.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Pentobarbital.
GemfibrozilThe metabolism of Gemfibrozil can be increased when combined with Pentobarbital.
GlipizideThe metabolism of Glipizide can be increased when combined with Pentobarbital.
GlutethimideThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Glutethimide.
GlyburideThe metabolism of Glyburide can be increased when combined with Pentobarbital.
GranisetronThe metabolism of Granisetron can be increased when combined with Pentobarbital.
GrepafloxacinThe metabolism of Grepafloxacin can be increased when combined with Pentobarbital.
GriseofulvinThe serum concentration of Griseofulvin can be decreased when it is combined with Pentobarbital.
GuanfacinePentobarbital may increase the hypotensive activities of Guanfacine.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Pentobarbital.
HalazepamThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Halazepam.
HalofantrineThe metabolism of Halofantrine can be increased when combined with Pentobarbital.
HaloperidolThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Hexobarbital.
Histamine PhosphateThe metabolism of Histamine Phosphate can be increased when combined with Pentobarbital.
HydralazinePentobarbital may increase the hypotensive activities of Hydralazine.
HydrochlorothiazidePentobarbital may increase the orthostatic hypotensive activities of Hydrochlorothiazide.
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Pentobarbital.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Pentobarbital.
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Pentobarbital.
HydroflumethiazidePentobarbital may increase the orthostatic hypotensive activities of Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Hydromorphone.
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be increased when combined with Pentobarbital.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.
HydroxyzineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Hydroxyzine.
IbrutinibThe serum concentration of Ibrutinib can be decreased when it is combined with Pentobarbital.
IdelalisibThe serum concentration of Idelalisib can be decreased when it is combined with Pentobarbital.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be increased when Ifosfamide is used in combination with Pentobarbital.
IloperidoneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Iloperidone.
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Pentobarbital.
ImipramineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Imipramine.
ImiquimodThe metabolism of Imiquimod can be increased when combined with Pentobarbital.
IndacaterolThe metabolism of Indacaterol can be increased when combined with Pentobarbital.
IndalpineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Indalpine.
IndapamidePentobarbital may increase the orthostatic hypotensive activities of Indapamide.
IndenololThe serum concentration of Indenolol can be decreased when it is combined with Pentobarbital.
IndinavirThe metabolism of Indinavir can be increased when combined with Pentobarbital.
Ipratropium bromideThe metabolism of Ipratropium bromide can be increased when combined with Pentobarbital.
IrbesartanPentobarbital may increase the hypotensive activities of Irbesartan.
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be reduced when Irinotecan is used in combination with Pentobarbital resulting in a loss in efficacy.
IsavuconazoniumThe serum concentration of the active metabolites of Isavuconazonium can be reduced when Isavuconazonium is used in combination with Pentobarbital resulting in a loss in efficacy.
IsofluraneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Isoflurane.
IsoniazidThe metabolism of Pentobarbital can be decreased when combined with Isoniazid.
Isosorbide DinitratePentobarbital may increase the hypotensive activities of Isosorbide Dinitrate.
Isosorbide MononitratePentobarbital may increase the hypotensive activities of Isosorbide Mononitrate.
IsoxsuprinePentobarbital may increase the hypotensive activities of Isoxsuprine.
IsradipinePentobarbital may increase the hypotensive activities of Isradipine.
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Pentobarbital.
IvabradineThe serum concentration of Ivabradine can be decreased when it is combined with Pentobarbital.
IvacaftorThe serum concentration of Ivacaftor can be decreased when it is combined with Pentobarbital.
IvermectinThe metabolism of Ivermectin can be increased when combined with Pentobarbital.
IxabepiloneThe serum concentration of Ixabepilone can be decreased when it is combined with Pentobarbital.
IxazomibThe serum concentration of Ixazomib can be decreased when it is combined with Pentobarbital.
KetamineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Ketobemidone.
KetoconazoleThe metabolism of Ketoconazole can be increased when combined with Pentobarbital.
LabetalolPentobarbital may increase the hypotensive activities of Labetalol.
LacidipineThe metabolism of Lacidipine can be increased when combined with Pentobarbital.
LamotrigineThe metabolism of Lamotrigine can be increased when combined with Pentobarbital.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Pentobarbital.
LansoprazoleThe metabolism of Lansoprazole can be increased when combined with Pentobarbital.
LapatinibThe serum concentration of Lapatinib can be decreased when it is combined with Pentobarbital.
LaquinimodThe metabolism of Laquinimod can be increased when combined with Pentobarbital.
LenvatinibThe metabolism of Lenvatinib can be increased when combined with Pentobarbital.
LercanidipineThe metabolism of Lercanidipine can be increased when combined with Pentobarbital.
LetrozoleThe metabolism of Letrozole can be increased when combined with Pentobarbital.
LevetiracetamThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Levetiracetam.
LevobunololPentobarbital may increase the hypotensive activities of Levobunolol.
LevobupivacaineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Levomilnacipran.
LevonorgestrelThe metabolism of Levonorgestrel can be increased when combined with Pentobarbital.
LevorphanolThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Levorphanol.
LevothyroxineThe metabolism of Levothyroxine can be increased when combined with Pentobarbital.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Pentobarbital.
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Pentobarbital.
LisinoprilPentobarbital may increase the hypotensive activities of Lisinopril.
LisurideThe metabolism of Lisuride can be increased when combined with Pentobarbital.
LithiumThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Lofentanil.
LomitapideThe metabolism of Lomitapide can be increased when combined with Pentobarbital.
LoperamideThe metabolism of Loperamide can be increased when combined with Pentobarbital.
LopinavirThe metabolism of Lopinavir can be increased when combined with Pentobarbital.
LoratadineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Pentobarbital.
LorcaserinThe metabolism of Lorcaserin can be increased when combined with Pentobarbital.
LosartanPentobarbital may increase the hypotensive activities of Losartan.
LovastatinThe metabolism of Lovastatin can be increased when combined with Pentobarbital.
LoxapineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Loxapine.
Lu AA21004The risk or severity of adverse effects can be increased when Pentobarbital is combined with Lu AA21004.
LuliconazoleThe serum concentration of Pentobarbital can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Pentobarbital can be decreased when it is combined with Lumacaftor.
LumefantrineThe serum concentration of Lumefantrine can be decreased when it is combined with Pentobarbital.
LurasidoneThe serum concentration of Lurasidone can be decreased when it is combined with Pentobarbital.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Pentobarbital.
MacitentanThe serum concentration of Macitentan can be decreased when it is combined with Pentobarbital.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.
Magnesium SulfateThe metabolism of Magnesium Sulfate can be increased when combined with Pentobarbital.
ManidipineThe metabolism of Manidipine can be increased when combined with Pentobarbital.
MannitolPentobarbital may increase the hypotensive activities of Mannitol.
MaprotilineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Maprotiline.
MaravirocThe serum concentration of Maraviroc can be decreased when it is combined with Pentobarbital.
MebendazoleThe metabolism of Mebendazole can be increased when combined with Pentobarbital.
MecamylaminePentobarbital may increase the hypotensive activities of Mecamylamine.
MeclizineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Medetomidine.
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be increased when combined with Pentobarbital.
MedrysoneThe serum concentration of Medrysone can be decreased when it is combined with Pentobarbital.
MefloquineThe metabolism of Mefloquine can be increased when combined with Pentobarbital.
MelatoninThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Melatonin.
MelengestrolThe serum concentration of Melengestrol can be decreased when it is combined with Pentobarbital.
MeloxicamThe metabolism of Meloxicam can be increased when combined with Pentobarbital.
MelperoneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Meprobamate.
MesoridazineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Methaqualone.
MethazolamidePentobarbital may increase the hypotensive activities of Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Methohexital.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Methotrimeprazine.
MethoxsalenThe metabolism of Methoxsalen can be increased when combined with Pentobarbital.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Methsuximide.
MethyclothiazidePentobarbital may increase the orthostatic hypotensive activities of Methyclothiazide.
MethyldopaPentobarbital may increase the hypotensive activities of Methyldopa.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Methylphenobarbital.
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Pentobarbital.
MethyltestosteroneThe metabolism of Methyltestosterone can be increased when combined with Pentobarbital.
MetipranololPentobarbital may increase the hypotensive activities of Metipranolol.
MetolazonePentobarbital may increase the orthostatic hypotensive activities of Metolazone.
MetoprololPentobarbital may increase the hypotensive activities of Metoprolol.
MetronidazoleThe metabolism of Metronidazole can be increased when combined with Pentobarbital.
MetyrosinePentobarbital may increase the sedative activities of Metyrosine.
MexiletineThe metabolism of Mexiletine can be increased when combined with Pentobarbital.
MianserinMianserin may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.
MianserinThe metabolism of Mianserin can be increased when combined with Pentobarbital.
MibefradilThe metabolism of Mibefradil can be increased when combined with Pentobarbital.
MiconazoleThe metabolism of Miconazole can be increased when combined with Pentobarbital.
MidazolamThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Midazolam.
MifepristoneThe serum concentration of Mifepristone can be decreased when it is combined with Pentobarbital.
MilnacipranThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.
MinoxidilPentobarbital may increase the hypotensive activities of Minoxidil.
MirabegronThe metabolism of Mirabegron can be increased when combined with Pentobarbital.
MirtazapinePentobarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Pentobarbital.
MoclobemideThe metabolism of Pentobarbital can be decreased when combined with Moclobemide.
ModafinilThe metabolism of Modafinil can be increased when combined with Pentobarbital.
MoexiprilPentobarbital may increase the hypotensive activities of Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Molindone.
MometasoneThe serum concentration of Mometasone can be decreased when it is combined with Pentobarbital.
MontelukastThe metabolism of Montelukast can be increased when combined with Pentobarbital.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Pentobarbital.
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be increased when combined with Pentobarbital.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.
NabiloneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Nabilone.
NadololPentobarbital may increase the hypotensive activities of Nadolol.
NalbuphineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Nalbuphine.
NaloxegolThe serum concentration of Naloxegol can be decreased when it is combined with Pentobarbital.
NaloxoneThe metabolism of Naloxone can be increased when combined with Pentobarbital.
NateglinideThe metabolism of Nateglinide can be increased when combined with Pentobarbital.
NebivololPentobarbital may increase the hypotensive activities of Nebivolol.
NefazodoneThe metabolism of Nefazodone can be increased when combined with Pentobarbital.
NelfinavirThe metabolism of Nelfinavir can be increased when combined with Pentobarbital.
NesiritidePentobarbital may increase the hypotensive activities of Nesiritide.
NetupitantThe serum concentration of Netupitant can be decreased when it is combined with Pentobarbital.
NevirapineThe metabolism of Nevirapine can be increased when combined with Pentobarbital.
NicardipinePentobarbital may increase the hypotensive activities of Nicardipine.
NicardipineThe metabolism of Pentobarbital can be decreased when combined with Nicardipine.
NicotineThe metabolism of Nicotine can be increased when combined with Pentobarbital.
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Pentobarbital.
NiguldipineThe metabolism of Niguldipine can be increased when combined with Pentobarbital.
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Pentobarbital.
NiludipineThe metabolism of Niludipine can be increased when combined with Pentobarbital.
NilvadipineThe metabolism of Nilvadipine can be increased when combined with Pentobarbital.
NimesulideThe metabolism of Nimesulide can be increased when combined with Pentobarbital.
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Pentobarbital.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Pentobarbital.
NisoldipineThe serum concentration of Nisoldipine can be decreased when it is combined with Pentobarbital.
NitrazepamThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Nitrazepam.
NitrendipineThe metabolism of Nitrendipine can be increased when combined with Pentobarbital.
NitroglycerinPentobarbital may increase the hypotensive activities of Nitroglycerin.
NitroprussidePentobarbital may increase the hypotensive activities of Nitroprusside.
Nitrous oxideThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Nitrous oxide.
NorethisteroneThe metabolism of Norethisterone can be increased when combined with Pentobarbital.
NorgestrelThe metabolism of Norgestrel can be increased when combined with Pentobarbital.
NormethadoneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Olanzapine.
OlaparibThe serum concentration of Olaparib can be decreased when it is combined with Pentobarbital.
OlmesartanPentobarbital may increase the hypotensive activities of Olmesartan.
OlopatadineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Olopatadine.
OmeprazoleThe metabolism of Omeprazole can be increased when combined with Pentobarbital.
OndansetronThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Opium.
OrphenadrinePentobarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Pentobarbital.
OsanetantThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Osanetant.
OsimertinibThe serum concentration of Osimertinib can be decreased when it is combined with Pentobarbital.
OspemifeneThe metabolism of Ospemifene can be increased when combined with Pentobarbital.
OxazepamThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Oxazepam.
OxprenololThe serum concentration of Oxprenolol can be decreased when it is combined with Pentobarbital.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Pentobarbital.
OxybuprocaineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Oxybuprocaine.
OxybutyninThe metabolism of Oxybutynin can be increased when combined with Pentobarbital.
OxycodoneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Oxymorphone.
PaclitaxelThe metabolism of Paclitaxel can be increased when combined with Pentobarbital.
PalbociclibThe serum concentration of Palbociclib can be decreased when it is combined with Pentobarbital.
PaliperidoneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Paliperidone.
PalonosetronThe metabolism of Palonosetron can be increased when combined with Pentobarbital.
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Pentobarbital.
PantoprazoleThe metabolism of Pantoprazole can be increased when combined with Pentobarbital.
PapaverinePentobarbital may increase the hypotensive activities of Papaverine.
ParaldehydePentobarbital may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Pentobarbital.
ParamethadioneThe metabolism of Paramethadione can be increased when combined with Pentobarbital.
ParamethasoneThe serum concentration of Paramethasone can be decreased when it is combined with Pentobarbital.
ParecoxibThe metabolism of Parecoxib can be increased when combined with Pentobarbital.
ParicalcitolThe metabolism of Paricalcitol can be increased when combined with Pentobarbital.
ParitaprevirThe metabolism of Paritaprevir can be increased when combined with Pentobarbital.
ParoxetineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Pentobarbital.
PenbutololPentobarbital may increase the hypotensive activities of Penbutolol.
PentamidineThe metabolism of Pentamidine can be increased when combined with Pentobarbital.
PentazocineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Pentazocine.
PerampanelThe serum concentration of Perampanel can be decreased when it is combined with Pentobarbital.
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Pentobarbital.
PergolideThe metabolism of Pergolide can be increased when combined with Pentobarbital.
PerhexilineThe metabolism of Perhexiline can be increased when combined with Pentobarbital.
PerindoprilPentobarbital may increase the hypotensive activities of Perindopril.
PermethrinThe metabolism of Permethrin can be increased when combined with Pentobarbital.
PerospironeThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Perphenazine.
PethidinePentobarbital may increase the central nervous system depressant (CNS depressant) activities of Pethidine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Pentobarbital.
PhenacetinThe metabolism of Phenacetin can be increased when combined with Pentobarbital.
PhenindioneThe metabolism of Phenindione can be increased when combined with Pentobarbital.
PhenobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Phenobarbital.
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be increased when combined with Pentobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Phenoxyethanol.
PhenprocoumonThe metabolism of Phenprocoumon can be increased when combined with Pentobarbital.
PhenytoinThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Phenytoin.
PilocarpineThe metabolism of Pilocarpine can be increased when combined with Pentobarbital.
PimecrolimusThe metabolism of Pimecrolimus can be increased when combined with Pentobarbital.
PimozideThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Pimozide.
PinacidilThe metabolism of Pinacidil can be increased when combined with Pentobarbital.
PinaveriumThe metabolism of Pinaverium can be increased when combined with Pentobarbital.
PindololPentobarbital may increase the hypotensive activities of Pindolol.
PioglitazoneThe metabolism of Pioglitazone can be increased when combined with Pentobarbital.
PipamperoneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Pizotifen.
PodofiloxThe metabolism of Podofilox can be increased when combined with Pentobarbital.
PolythiazidePentobarbital may increase the orthostatic hypotensive activities of Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Pomalidomide.
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Pentobarbital.
PosaconazoleThe metabolism of Posaconazole can be increased when combined with Pentobarbital.
PractololThe serum concentration of Practolol can be decreased when it is combined with Pentobarbital.
PramipexolePentobarbital may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Pramocaine.
PrasugrelThe metabolism of Prasugrel can be increased when combined with Pentobarbital.
PravastatinThe metabolism of Pravastatin can be increased when combined with Pentobarbital.
PrazepamThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Prazepam.
PraziquantelThe serum concentration of Praziquantel can be decreased when it is combined with Pentobarbital.
PrazosinPentobarbital may increase the hypotensive activities of Prazosin.
PrednicarbateThe serum concentration of Prednicarbate can be decreased when it is combined with Pentobarbital.
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Pentobarbital.
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Pentobarbital.
PregabalinThe metabolism of Pregabalin can be increased when combined with Pentobarbital.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Pentobarbital.
PregnenoloneThe serum concentration of Pregnenolone can be decreased when it is combined with Pentobarbital.
PrenylamineThe metabolism of Prenylamine can be increased when combined with Pentobarbital.
PrilocaineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Prilocaine.
PrimaquineThe metabolism of Primaquine can be increased when combined with Pentobarbital.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Pentobarbital.
ProcaineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Procaine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Prochlorperazine.
ProgesteroneThe metabolism of Progesterone can be increased when combined with Pentobarbital.
ProguanilThe metabolism of Proguanil can be increased when combined with Pentobarbital.
PromazineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Promethazine.
PropacetamolThe metabolism of Propacetamol can be increased when combined with Pentobarbital.
PropafenoneThe serum concentration of Propafenone can be decreased when it is combined with Pentobarbital.
ProparacaineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Proparacaine.
PropofolThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Propoxycaine.
PropranololPentobarbital may increase the hypotensive activities of Propranolol.
ProtriptylineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Pentobarbital is combined with PSD502.
PyrazinamideThe metabolism of Pyrazinamide can be increased when combined with Pentobarbital.
PyridoxineThe metabolism of Pentobarbital can be increased when combined with Pyridoxine.
QuazepamThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Quazepam.
QuetiapinePentobarbital may increase the hypotensive activities of Quetiapine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Pentobarbital.
QuinacrineThe metabolism of Quinacrine can be increased when combined with Pentobarbital.
QuinaprilPentobarbital may increase the hypotensive activities of Quinapril.
QuinethazonePentobarbital may increase the orthostatic hypotensive activities of Quinethazone.
QuinidineThe metabolism of Quinidine can be increased when combined with Pentobarbital.
QuinineThe metabolism of Quinine can be increased when combined with Pentobarbital.
RabeprazoleThe metabolism of Rabeprazole can be increased when combined with Pentobarbital.
RaloxifeneThe metabolism of Raloxifene can be increased when combined with Pentobarbital.
RamelteonThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Ramelteon.
RamiprilPentobarbital may increase the hypotensive activities of Ramipril.
RanolazineThe serum concentration of Ranolazine can be decreased when it is combined with Pentobarbital.
ReboxetineThe metabolism of Reboxetine can be increased when combined with Pentobarbital.
RegorafenibThe serum concentration of Regorafenib can be decreased when it is combined with Pentobarbital.
RemifentanilThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Remoxipride.
RepaglinideThe metabolism of Repaglinide can be increased when combined with Pentobarbital.
ReserpinePentobarbital may increase the hypotensive activities of Reserpine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Pentobarbital.
RetapamulinThe metabolism of Retapamulin can be increased when combined with Pentobarbital.
RifabutinThe metabolism of Rifabutin can be increased when combined with Pentobarbital.
RifampicinThe metabolism of Rifampicin can be increased when combined with Pentobarbital.
RilpivirineThe metabolism of Rilpivirine can be increased when combined with Pentobarbital.
RimexoloneThe serum concentration of Rimexolone can be decreased when it is combined with Pentobarbital.
RimonabantThe metabolism of Rimonabant can be increased when combined with Pentobarbital.
RiociguatPentobarbital may increase the hypotensive activities of Riociguat.
RisedronateThe metabolism of Risedronate can be increased when combined with Pentobarbital.
RisperidoneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Risperidone.
RitonavirThe metabolism of Ritonavir can be increased when combined with Pentobarbital.
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Pentobarbital.
RofecoxibThe metabolism of Rofecoxib can be increased when combined with Pentobarbital.
RoflumilastThe serum concentration of Roflumilast can be decreased when it is combined with Pentobarbital.
RolapitantThe serum concentration of Rolapitant can be decreased when it is combined with Pentobarbital.
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Pentobarbital.
RomifidineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Romifidine.
RopinirolePentobarbital may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Pentobarbital.
RosuvastatinThe metabolism of Rosuvastatin can be increased when combined with Pentobarbital.
RotigotinePentobarbital may increase the sedative activities of Rotigotine.
RoxithromycinThe metabolism of Roxithromycin can be increased when combined with Pentobarbital.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Pentobarbital.
RuxolitinibThe metabolism of Ruxolitinib can be increased when combined with Pentobarbital.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Pentobarbital is combined with S-Ethylisothiourea.
SalmeterolThe metabolism of Salmeterol can be increased when combined with Pentobarbital.
SaquinavirThe metabolism of Saquinavir can be increased when combined with Pentobarbital.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Pentobarbital.
ScopolamineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Secobarbital.
SelegilineThe metabolism of Selegiline can be increased when combined with Pentobarbital.
SelexipagThe metabolism of Selexipag can be increased when combined with Pentobarbital.
SeratrodastThe metabolism of Seratrodast can be increased when combined with Pentobarbital.
SertindoleThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Sertraline.
SertralineThe metabolism of Pentobarbital can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Sevoflurane.
SibutramineThe metabolism of Sibutramine can be increased when combined with Pentobarbital.
SildenafilThe metabolism of Sildenafil can be increased when combined with Pentobarbital.
SilodosinThe metabolism of Silodosin can be increased when combined with Pentobarbital.
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Pentobarbital.
SimvastatinThe metabolism of Simvastatin can be increased when combined with Pentobarbital.
SirolimusThe metabolism of Sirolimus can be increased when combined with Pentobarbital.
SitagliptinThe metabolism of Sitagliptin can be increased when combined with Pentobarbital.
Sodium oxybateThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Sodium oxybate.
SolifenacinThe metabolism of Solifenacin can be increased when combined with Pentobarbital.
SomatostatinThe risk or severity of adverse effects can be increased when Somatostatin is combined with Pentobarbital.
SonidegibThe serum concentration of Sonidegib can be decreased when it is combined with Pentobarbital.
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Pentobarbital.
SotalolPentobarbital may increase the hypotensive activities of Sotalol.
SpiramycinThe metabolism of Spiramycin can be increased when combined with Pentobarbital.
SpironolactonePentobarbital may increase the hypotensive activities of Spironolactone.
StiripentolThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Sufentanil.
SulfadiazineThe metabolism of Sulfadiazine can be increased when combined with Pentobarbital.
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be increased when combined with Pentobarbital.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be increased when combined with Pentobarbital.
SulpirideThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Sulpiride.
SunitinibThe serum concentration of Sunitinib can be decreased when it is combined with Pentobarbital.
SuvorexantThe serum concentration of Suvorexant can be decreased when it is combined with Pentobarbital.
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Pentobarbital.
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be increased when combined with Pentobarbital.
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be increased when combined with Pentobarbital.
TacrolimusThe metabolism of Tacrolimus can be increased when combined with Pentobarbital.
TadalafilThe serum concentration of Tadalafil can be decreased when it is combined with Pentobarbital.
TamoxifenThe metabolism of Tamoxifen can be increased when combined with Pentobarbital.
TamsulosinThe metabolism of Tamsulosin can be increased when combined with Pentobarbital.
TapentadolThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Tapentadol.
TasimelteonThe serum concentration of Tasimelteon can be decreased when it is combined with Pentobarbital.
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Pentobarbital.
TasosartanThe metabolism of Tasosartan can be increased when combined with Pentobarbital.
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be increased when combined with Pentobarbital.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Pentobarbital.
TelithromycinThe metabolism of Telithromycin can be increased when combined with Pentobarbital.
TelmisartanPentobarbital may increase the hypotensive activities of Telmisartan.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Pentobarbital.
TemsirolimusThe metabolism of Temsirolimus can be increased when combined with Pentobarbital.
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Pentobarbital.
TerazosinPentobarbital may increase the hypotensive activities of Terazosin.
TerbinafineThe metabolism of Terbinafine can be increased when combined with Pentobarbital.
TerfenadineThe metabolism of Terfenadine can be increased when combined with Pentobarbital.
TesmilifeneThe metabolism of Tesmilifene can be increased when combined with Pentobarbital.
TestosteroneThe metabolism of Testosterone can be increased when combined with Pentobarbital.
TetrabenazineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Tetracaine.
TetracyclineThe metabolism of Tetracycline can be increased when combined with Pentobarbital.
TetrodotoxinThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Tetrodotoxin.
ThalidomidePentobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Pentobarbital.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Pentobarbital.
ThiamylalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Thiopental.
ThioridazineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Thioridazine.
ThiotepaThe metabolism of Thiotepa can be increased when combined with Pentobarbital.
ThiothixeneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Tiagabine.
TianeptineThe metabolism of Tianeptine can be increased when combined with Pentobarbital.
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Pentobarbital resulting in a loss in efficacy.
TiclopidineThe metabolism of Ticlopidine can be increased when combined with Pentobarbital.
TiletamineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Tiletamine.
TimololPentobarbital may increase the hypotensive activities of Timolol.
TinidazoleThe metabolism of Tinidazole can be increased when combined with Pentobarbital.
TiotropiumThe metabolism of Tiotropium can be increased when combined with Pentobarbital.
TipranavirThe metabolism of Tipranavir can be increased when combined with Pentobarbital.
TixocortolThe serum concentration of Tixocortol can be decreased when it is combined with Pentobarbital.
TizanidinePentobarbital may increase the hypotensive activities of Tizanidine.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Pentobarbital.
TofacitinibThe serum concentration of Tofacitinib can be decreased when it is combined with Pentobarbital.
TolcaponeThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Tolcapone.
Tolfenamic AcidThe metabolism of Tolfenamic Acid can be increased when combined with Pentobarbital.
TolterodineThe metabolism of Tolterodine can be increased when combined with Pentobarbital.
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Pentobarbital.
TopiramateThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Topiramate.
TorasemidePentobarbital may increase the hypotensive activities of Torasemide.
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Pentobarbital.
TrabectedinThe serum concentration of Trabectedin can be decreased when it is combined with Pentobarbital.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Pentobarbital.
TrandolaprilPentobarbital may increase the hypotensive activities of Trandolapril.
TranilastThe metabolism of Tranilast can be increased when combined with Pentobarbital.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Tranylcypromine.
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be increased when combined with Pentobarbital.
TrazodoneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Trazodone.
TretinoinThe metabolism of Tretinoin can be increased when combined with Pentobarbital.
TriamcinoloneThe serum concentration of Triamcinolone can be decreased when it is combined with Pentobarbital.
TriamterenePentobarbital may increase the hypotensive activities of Triamterene.
TriazolamThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Triazolam.
TrichlormethiazidePentobarbital may increase the orthostatic hypotensive activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Triflupromazine.
TrimethadioneThe metabolism of Trimethadione can be increased when combined with Pentobarbital.
TrimethoprimThe metabolism of Trimethoprim can be increased when combined with Pentobarbital.
TrimipramineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Triprolidine.
TroglitazoneThe metabolism of Troglitazone can be increased when combined with Pentobarbital.
TroleandomycinThe metabolism of Troleandomycin can be increased when combined with Pentobarbital.
UdenafilThe metabolism of Udenafil can be increased when combined with Pentobarbital.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Pentobarbital.
ValdecoxibThe metabolism of Valdecoxib can be increased when combined with Pentobarbital.
Valproic AcidThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Valproic Acid.
ValsartanPentobarbital may increase the hypotensive activities of Valsartan.
VandetanibThe serum concentration of Vandetanib can be decreased when it is combined with Pentobarbital.
VanoxerineThe metabolism of Vanoxerine can be increased when combined with Pentobarbital.
VardenafilThe metabolism of Vardenafil can be increased when combined with Pentobarbital.
VemurafenibThe serum concentration of Vemurafenib can be decreased when it is combined with Pentobarbital.
VenlafaxineThe metabolism of Venlafaxine can be increased when combined with Pentobarbital.
VerapamilPentobarbital may increase the hypotensive activities of Verapamil.
VicrivirocThe metabolism of Vicriviroc can be increased when combined with Pentobarbital.
VigabatrinThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Vigabatrin.
VilanterolThe metabolism of Vilanterol can be increased when combined with Pentobarbital.
VilazodoneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Vilazodone.
VinblastineThe metabolism of Vinblastine can be increased when combined with Pentobarbital.
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Pentobarbital.
VindesineThe metabolism of Vindesine can be increased when combined with Pentobarbital.
VinorelbineThe metabolism of Vinorelbine can be increased when combined with Pentobarbital.
VismodegibThe metabolism of Vismodegib can be increased when combined with Pentobarbital.
VorapaxarThe serum concentration of Vorapaxar can be decreased when it is combined with Pentobarbital.
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Pentobarbital.
VoriconazoleThe metabolism of Pentobarbital can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Vortioxetine.
WarfarinThe metabolism of Warfarin can be increased when combined with Pentobarbital.
XylazineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Xylazine.
XylometazolineThe metabolism of Xylometazoline can be increased when combined with Pentobarbital.
YohimbineThe metabolism of Yohimbine can be increased when combined with Pentobarbital.
ZafirlukastThe metabolism of Zafirlukast can be increased when combined with Pentobarbital.
ZalcitabineThe metabolism of Zalcitabine can be increased when combined with Pentobarbital.
ZaleplonThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Zaleplon.
ZiconotideThe metabolism of Ziconotide can be increased when combined with Pentobarbital.
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Pentobarbital.
ZidovudineThe metabolism of Zidovudine can be increased when combined with Pentobarbital.
ZileutonThe metabolism of Zileuton can be increased when combined with Pentobarbital.
ZimelidineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Pentobarbital.
ZolazepamThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Zolpidem.
ZomepiracThe metabolism of Zomepirac can be increased when combined with Pentobarbital.
ZonisamideThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Zotepine.
ZuclopenthixolThe serum concentration of Zuclopenthixol can be decreased when it is combined with Pentobarbital.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Pentobarbital.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Steinbach JH, Akk G: Modulation of GABA(A) receptor channel gating by pentobarbital. J Physiol. 2001 Dec 15;537(Pt 3):715-33. [PubMed:11744750 ]
  2. Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57. [PubMed:14579514 ]
  3. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
  4. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
  5. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  6. Davies DL, McCauley LD, Bolger MB, Alkana RL: Pressure-sensitive and -insensitive coupling in gamma-aminobutyric acid(A) receptors. Psychopharmacology (Berl). 2001 Oct;157(4):401-10. [PubMed:11605100 ]
  7. Rahman M, Zhu D, Lindblad C, Johansson IM, Holmberg E, Isaksson M, Taube M, Backstrom T, Wang MD: GABA-site antagonism and pentobarbital actions do not depend on the alpha-subunit type in the recombinant rat GABA receptor. Acta Physiol (Oxf). 2006 Aug;187(4):479-88. [PubMed:16866778 ]
  8. Feigenspan A, Weiler R: Electrophysiological properties of mouse horizontal cell GABAA receptors. J Neurophysiol. 2004 Nov;92(5):2789-801. Epub 2004 Jul 7. [PubMed:15240758 ]
  9. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  10. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  11. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular Weight:
51325.85 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular Weight:
55164.055 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA4
Uniprot ID:
P48169
Molecular Weight:
61622.645 Da
References
  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transporter activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA5
Uniprot ID:
P31644
Molecular Weight:
52145.645 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA6
Uniprot ID:
Q16445
Molecular Weight:
51023.69 Da
References
  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
  2. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Ligand-gated ion channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions.
Gene Name:
CHRNA4
Uniprot ID:
P43681
Molecular Weight:
69956.47 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797 ]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Toxic substance binding
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin.
Gene Name:
CHRNA7
Uniprot ID:
P36544
Molecular Weight:
56448.925 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797 ]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Ionotropic glutamate receptor activity
Specific Function:
Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and t...
Gene Name:
GRIA2
Uniprot ID:
P42262
Molecular Weight:
98820.32 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Kainate selective glutamate receptor activity
Specific Function:
Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inacti...
Gene Name:
GRIK2
Uniprot ID:
Q13002
Molecular Weight:
102582.475 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
positive allosteric modulator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. ChEMBL Compound Report Card [Link]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Voltage-gated cation channel activity
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. This protein plays a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition and learning. It mediates neuronal functions in glutamate neurotransmission. Is involved in the cell surface targeting of NMDA receptors (By similarity).
Components:
NameUniProt IDDetails
Glutamate receptor ionotropic, NMDA 1Q05586 Details
Glutamate receptor ionotropic, NMDA 2AQ12879 Details
Glutamate receptor ionotropic, NMDA 2BQ13224 Details
Glutamate receptor ionotropic, NMDA 2CQ14957 Details
Glutamate receptor ionotropic, NMDA 2DO15399 Details
Glutamate receptor ionotropic, NMDA 3AQ8TCU5 Details
Glutamate receptor ionotropic, NMDA 3BO60391 Details
References
  1. Daniell LC: Effect of anesthetic and convulsant barbiturates on N-methyl-D-aspartate receptor-mediated calcium flux in brain membrane vesicles. Pharmacology. 1994 Nov;49(5):296-307. [PubMed:7862741 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23